-
Biotech ETFs Hitting New Highs On Takeover News (FBT, PBE, ITMN)
Wednesday, August 27, 2014 - 3:22pm | 588Read More...The biotechnology industry had a big day Monday after the news of Swiss pharmaceutical giant Roche agreed to acquire the U.S biotech company InterMune (NASDAQ: ITMN) for $8.3 billion in cash. The deal breaks down to Roche paying $74.00 a share for InterMune, a 38 percent premium from its...
-
Market Wrap For February 25: Markets End The Day Relatively Flat
Tuesday, February 25, 2014 - 5:38pm | 2952Read More...U.S. stocks fell on Tuesday as investors found a decline in consumer confidence as reason enough to keep stocks from moving higher. The S&P 500 retreated from its record all time high set yesterday but took a run above the 1,850 level in the late morning. The all time high for the index is...
-
Thomas Weisel Partners More Than Double InterMune (ITMN) Price Target To $55
Wednesday, March 10, 2010 - 9:15am | 202Read More...Thomas Weisel Partners analyst Stephen Willey maintained his Overweight rating for shares of InterMune, Inc. (Nasdaq: ITMN) and raised the price target from $26 to $55. The day before, a panel at the Food and Drug Administration recommended InterMune's pirfenidone for the treatment of idiopathic...
-
Wells Fargo Securities Rates InterMune (ITMN) Market Perform
Monday, March 8, 2010 - 12:37pm | 167Read More...Wells Fargo Securities analysts Aaron Reames and Matthew J. Andrews rated shares of InterMune, Inc. (Nasdaq: ITMN) Market Perform. The analysts questioned whether or not the FDA would accept InterMune's use of Forced Vital Capacity, as opposed to Overall Survival as the appropriate endpoint for the...
